Author pages are created from data sourced from our academic publisher partnerships and public sources.
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
BACKGROUND Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain… Expand
An international consensus approach to the management of atypical hemolytic uremic syndrome in children
Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease largely of complement dysregulation. This advance facilitated the development of novel, rational treatment… Expand
Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome
- G. Ariceta, N. Beşbaş, +10 authors The European Paediatric Study Group for Hus
- Pediatric Nephrology
- 1 April 2009
This guideline for the investigation and initial treatment of atypical hemolytic uremic syndrome (HUS) is intended to offer an approach based on opinion, as evidence is lacking. It builds on the… Expand
A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders.
The diagnostic terms hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are based on historical and overlapping clinical descriptions. Advances in understanding some of the… Expand
Pathogenesis of Shiga Toxin-Associated Hemolytic Uremic Syndrome
The aim of this review is to examine recent advances in experimental and clinical research relevant to the pathogenesis of diarrhea-associated hemolytic uremic syndrome with special reference to… Expand
Interleukin 8 Receptor Deficiency Confers Susceptibility to Acute Experimental Pyelonephritis and May Have a Human Counterpart
- B. Frendéus, G. Godaly, L. Hang, D. Karpman, Ann-Charlotte Lundstedt, C. Svanborg
- The Journal of experimental medicine
- 18 September 2000
Neutrophils migrate to infected mucosal sites that they protect against invading pathogens. Their interaction with the epithelial barrier is controlled by CXC chemokines and by their receptors. This… Expand
Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome.
This study presents evidence that human platelets bind lipopolysaccharide (LPS) from enterohemorrhagic Escherichia coli (EHEC) through a complex of toll-like receptor 4 (TLR4) and CD62, leading to… Expand
An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome
AbstractBackgroundIn 2009, the European Paediatric Study Group for Haemolytic Uraemic Syndrome (HUS) published a clinical practice guideline for the investigation and initial therapy of… Expand
Apoptosis of Renal Cortical Cells in the Hemolytic-Uremic Syndrome: In Vivo and In Vitro Studies
- D. Karpman, A. Håkansson, +4 authors C. Svanborg
- Biology, Medicine
- Infection and Immunity
- 1 February 1998
ABSTRACT This study examined apoptotic cell death associated with Shiga-like toxin (Stx)-producing Escherichia coli. Renal cortices from three children with postenteropathic hemolytic-uremic syndrome… Expand
Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.
Hemolytic uremic syndrome (HUS) is commonly associated with Shiga toxin (Stx)-producing Escherichia coli O157:H7 infection. This study examined patient samples for complement activation on… Expand